PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

PDS Biotech reported full-year 2025 financial results and provided an update on its PDS0101 Phase 3 program and PDS01ADC clinical advancement. The company amended the VERSATILE-003 Phase 3 clinical trial protocol to incorporate progression-free survival as an interim primary endpoint, potentially shortening trial duration and reducing costs. Early results from an NCI-led trial investigating PDS01ADC demonstrated encouraging median progression-free survival of 9.6 months and a median PSA decline of 40%. The company strengthened its intellectual property estate with new patents granted in the US and Japan, extending market protection into the 2040s.